Becker David J, Gordon Ram Y, Morris Patti B, Yorko Jacqueline, Gordon Y Jerold, Li Mingyao, Iqbal Nayyar
Division of Cardiology, Chestnut Hill Hospital, University of Pennsylvania Health System, Philadelphia, PA, USA.
Mayo Clin Proc. 2008 Jul;83(7):758-64. doi: 10.4065/83.7.758.
To compare the lipid-lowering effects of an alternative regimen (lifestyle changes, red yeast rice, and fish oil) with a standard dose of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin).
This randomized trial enrolled 74 patients with hypercholesterolemia who met Adult Treatment Panel III criteria for primary prevention using statin therapy. All participants were randomized to an alternative treatment group (AG) or to receive simvastatin (40 mg/d) in this open-label trial conducted between April 1, 2006, and June 30, 2006. The alternative treatment included therapeutic lifestyle changes, ingestion of red yeast rice, and fish oil supplements for 12 weeks. The simvastatin group received medication and traditional counseling. The primary outcome measure was the percentage change in low-density lipoprotein cholesterol (LDL-C). Secondary measures were changes in other lipoproteins and weight loss.
There was a statistically significant reduction in LDL-C levels in both the AG (-42.4%+/-15%) (P<.001) and the simvastatin group (-39.6%+/-20%) (P<.001). No significant differences were noted between groups. The AG also demonstrated significant reductions in triglycerides (-29% vs -9.3%; 95% confidence interval, -61 to -11.7; P=.003) and weight (-5.5% vs -0.4%; 95% confidence interval, -5.5 to -3.4; P<.001) compared with the simvastatin group.
Lifestyle changes combined with ingestion of red yeast rice and fish oil reduced LDL-C in proportions similar to standard therapy with simvastatin. Pending confirmation in larger trials, this multifactorial, alternative approach to lipid lowering has promise for a subset of patients unwilling or unable to take statins.
比较一种替代疗法(生活方式改变、红曲米和鱼油)与标准剂量的3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂(他汀类药物)的降脂效果。
这项随机试验纳入了74例符合成人治疗小组III标准、需使用他汀类药物进行一级预防的高胆固醇血症患者。在2006年4月1日至2006年6月30日进行的这项开放标签试验中,所有参与者被随机分配至替代治疗组(AG)或接受辛伐他汀(40毫克/天)治疗。替代治疗包括治疗性生活方式改变、服用红曲米和鱼油补充剂,为期12周。辛伐他汀组接受药物治疗和传统咨询。主要结局指标是低密度脂蛋白胆固醇(LDL-C)的百分比变化。次要指标是其他脂蛋白的变化和体重减轻。
AG组(-42.4%±15%)(P<0.001)和辛伐他汀组(-39.6%±20%)(P<0.001)的LDL-C水平均有统计学意义的降低。两组之间未发现显著差异。与辛伐他汀组相比,AG组的甘油三酯也有显著降低(-29%对-9.3%;95%置信区间,-61至-11.7;P=0.003)和体重减轻(-5.5%对-0.4%;95%置信区间,-5.5至-3.4;P<0.001)。
生活方式改变联合服用红曲米和鱼油降低LDL-C的比例与辛伐他汀标准治疗相似。在更大规模试验得到证实之前,这种多因素的替代降脂方法对一部分不愿或无法服用他汀类药物的患者有前景。